Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

Bryan Johnson injected himself with ketamine, a hallucinogen favored by Elon Musk, for 15 days. He used a helmet from his ...

However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine. This article examines Medicare coverage for ketamine infusion ...

Esketamine, a molecular relative of regular ketamine, was approved as a TRD treatment in 2019, but until now, it had to be taken alongside a second, traditional antidepressant. Now, the new FDA ...

Ketamine molecules contain two parts: S-ketamine (esketamine), which is like the left hand, and R-ketamine, which is like the right hand, McClure said. “Standard ketamine is a mixture of the two ...

Esketamine, a derivative of ketamine, is a rapid-acting antidepressant. Previously, it was approved in combination with oral antidepressants for individuals with treatment-resistant depression.

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

Trump’s “first buddy” Elon Musk made a lively, chaotic and unpredictable appearance at the Conservative Political Action ...